Immunotherapy for the prevention and treatment of type 1 diabetes: optimizing the path from bench to bedside.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. A randomized trial of oral gamma aminobutyric acid (GABA) or the combination of GABA with glutamic acid decarboxylase (GAD) on pancreatic islet endocrine function in children with newly diagnosed type 1 diabetes.Nature communications · 2022
   Trial
2. Latent Autoimmune Diabetes in Adults: Diagnostic and Therapeutic Challenges.Cureus · 2025
   Article
3. Status of islet transplantation and innovations to sustainable outcomes: novel sites, cell sources, and drug delivery strategies.Frontiers in transplantation · 2024
   Review
4. Editorial: Developing strategies to improve diabetes management in college-going young adults.Frontiers in endocrinology · 2024
   Article
5. Nanotargeted Delivery of Immune Therapeutics in Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2023
   Article
6. Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.Diabetes care · 2022
   Article
7. Transcriptional networks in at-risk individuals identify signatures of type 1 diabetes progression.Science translational medicine · 2021
   Article
8. Sibling method increases risk assessment estimates for type 1 diabetes.PloS one · 2017
   Article
9. The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.Current diabetes reports · 2016
   Review
10. HCELL Expression on Murine MSC Licenses Pancreatotropism and Confers Durable Reversal of Autoimmune Diabetes in NOD Mice.Stem cells (Dayton, Ohio) · 2015
    Article
11. Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice.PloS one · 2015
    Article
12. Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model.Diabetes · 2014
    Article
13. IL-7 receptor α blockade, an off-switch for autoreactive T cells.Proceedings of the National Academy of Sciences of the United States of America · 2012
    Article
14. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes.Diabetes · 2012
    Article
15. Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment.Journal of autoimmunity · 2011
    Article
16. Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.Nature reviews. Drug discovery · 2011
    Review
17. Immunomodulation with microbial vaccines to prevent type 1 diabetes mellitus.Nature reviews. Endocrinology · 2010
    Review
18. Diabetes mellitus: new challenges and innovative therapies.The EPMA journal · 2010
    Article
19. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.Diabetes care · 2009
    Article

Corrections and comments

• Commented on by
  Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as